If you have been reading about alpha-MSH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
The sodium–potassium pump (sodium–potassium adenosine triphosphatase, also known as Na+/K+-ATPase, Na+/K+ pump, or sodium–potassium ATPase) is an enzyme (an electrogenic transmembrane ATPase) found in the cell membrane of all animal cells. It performs several functions in cell physiology. The Na+/K+-ATPase enzyme is an enzyme involved in active transport (i.e. it uses energy from ATP). For every ATP molecule that the pump uses, three sodium ions are exported and two potassium ions are imported. Thus, there is a net export of a single positive charge per pump cycle. The net effect is an extracellular concentration of sodium ions 5 times the intracellular concentration, and an intracellular concentration of potassium ions 30 times the extracellular concentration. The sodium–potassium pump was discovered in 1957 by the Danish scientist Jens Christian Skou, who was awarded a Nobel Prize for his work in 1997. Its discovery marked an important step forward in the understanding of how ions get into and out of cells, and its particular significance for excitable cells such as nerve cells, which depend on this pump to respond to stimuli and transmit impulses. All mammals have four different sodium pump sub-types, or isoforms. Each has unique properties and tissue expression patterns. Sodium–potassium ATPase belongs to the family of P-type ATPases.
== Examples == Mastocytosis, including mast cell activation syndrome and eosinophilic esophagitis Chronic fatigue syndrome Systemic vasculitis e.g. SLE, PAN Sarcoidosis – a disease that mainly affects the lungs, brain, joints and eyes, found most often in young African-American women. Hypothyroidism – where the thyroid gland produces too little thyroid hormones. Diabetes mellitus – an imbalance in blood glucose (sugar) levels. Fibromyalgia Ehlers-Danlos syndromes - an inherited connective tissue disorder with multiple subcategories Adrenal insufficiency – where the adrenal glands don't produce enough steroid hormones Coeliac disease – an autoimmune disease triggered by gluten consumption, which may involve several organs and cause a variety of symptoms, or be completely asymptomatic. Ulcerative colitis – an inflammatory bowel disease Crohn's disease – an inflammatory bowel disease Hypertension (high blood pressure) Metabolic syndrome AIDS – a disease caused by a virus that cripples the body's immune defenses. Graves' disease – a thyroid disorder, most often in women, which can cause a goiter (swelling in the front part of the neck) and protruding eyes. Systemic lupus erythematosus – a connective tissue disorder involving mainly the skin, joints and kidneys. Rheumatoid arthritis – an inflammatory disease which mainly attacks the joints. But can also affect a person's skin, eyes, lungs and mouth.
Dissimilatory denitrification is widely used in the removal of nitrate and nitrite from municipal wastewater. An excess of nitrate can lead to eutrophication of waterways into which treated water is released. Elevated nitrite levels in drinking water can lead to problems due to its toxicity. Denitrification converts both compounds into harmless nitrogen gas. Specific types of anaerobic respiration are also critical in bioremediation, which uses microorganisms to convert toxic chemicals into less-harmful molecules to clean up contaminated beaches, aquifers, lakes, and oceans. For example, toxic arsenate or selenate can be reduced to less toxic compounds by various anaerobic bacteria via anaerobic respiration. The reduction of chlorinated chemical pollutants, such as vinyl chloride and carbon tetrachloride, also occurs through anaerobic respiration. Anaerobic respiration is useful in generating electricity in microbial fuel cells, which employ bacteria that respire solid electron acceptors (such as oxidized iron) to transfer electrons from reduced compounds to an electrode. This process can simultaneously degrade organic carbon waste and generate electricity.
=== Mouse-human hybrid === A mouse-human hybrid is a genetically modified mouse whose genome has both mouse and human genes, thus being a murine form of a human-animal hybrid. For example, genetically modified mice may be born with human leukocyte antigen genes in order to provide a more realistic environment when introducing human white blood cells into them in order to study immune system responses. One such application is the identification of hepatitis C virus (HCV) peptides that bind to HLA, and that can be recognized by the human immune system, thereby potentially being targets for future vaccines against HCV.
Vitamin K is absorbed along with dietary fat from the small intestine and transported by chylomicrons in the circulation. Most of vitamin K1 is carried by triacylglycerol-rich lipoproteins (TRL) and rapidly cleared by the liver; only a small amount is released into the circulation and carried by LDL-C and HDL-C. MK-4 is carried by the same lipoproteins (TRL, LDL-C, and HDL-C) and cleared fast as well. The long-chain menaquinones are absorbed in the same way as vitamin K1 and MK-4 but are efficiently redistributed by the liver in predominantly LDL-C (VLDL-C). Since LDL-C has a long half-life in the circulation, these menaquinones can circulate for extended times resulting in higher bioavailability for extra-hepatic tissues as compared to vitamin K1 and MK-4. Accumulation of vitamin K in extra-hepatic tissues has direct relevance to vitamin K functions not related to hemostasis.
Sources: en.wikipedia.org
Hyperacute rejection occurs when, before the transplantation, the recipient has preformed anti-HLA antibodies, perhaps by previous blood transfusions (donor tissue that includes lymphocytes expressing HLA molecules), by anti-HLA generated during pregnancy (directed at the father's HLA displayed by the fetus), or by previous transplantation; Acute cellular rejection occurs when the recipient's T lymphocytes are activated by the donor tissue, causing damage via mechanisms such as direct cytotoxicity from CD8 cells. Acute humoral rejection and chronic disfunction occurs when the recipient's anti-HLA antibodies form directed at HLA molecules present on endothelial cells of the transplanted tissue. In all of the above situations, immunity is directed at the transplanted organ, sustaining lesions. A cross-reaction test between potential donor cells and recipient serum seeks to detect presence of preformed anti-HLA antibodies in the potential recipient that recognize donor HLA molecules, so as to prevent hyperacute rejection. In normal circumstances, compatibility between HLA-A, -B, and -DR molecules is assessed. The higher the number of incompatibilities, the lower the five-year survival rate. Global databases of donor information enhance the search for compatible donors. The involvement in allogeneic transplant rejection appears to be an ancient feature of MHC molecules, because also in fish associations between transplant rejections and (mis-)matching of MHC class I and MHC class II were observed.
== Research and career == Parsons joined King's College London as a Royal Society University Research Fellow in 2005. She was promoted to Reader in 2013, and Professor in 2015. Parsons investigates the fundamental mechanisms that drive cell adhesion and migration using microscopy, molecular biology and three-dimensional simulations. She uses a confocal super-resolution microscope and Total internal reflection fluorescence microscope to image dynamic events over long periods. Whilst adhesion is critical to normal cellular function (e.g. development and homeostasis), it also drives cancer and fibrosis. In particular, Parsons focuses on integrins, and their behaviour in the extracellular matrix. By comparing "normal" cells with cancer cells, Parsons identified that the likelihood of cell invasion depended on the duration and chemistry of their adhesion with the matrix. Beyond fundamental cellular processes, Parsons has studied wound healing and inflammation using skin and lung epithelial cells. Parsons founded UKRI Technology Touching Life Integrated Biological Imaging Network, a multi-university, multidisciplinary research effort focussed on the development of strategies to understand and combat human disease. The network looks to understand the signalling hierarchy of cell adhesion, the molecular cues that regulate cell behaviour and the tissue mechanics that control cell growth. In 2017, Parsons was appointed to the executive committee of the Royal Microscopical Society. She is Editor in Chief of The International Journal of Biochemistry & Cell Biology.
== History == Cerebras Systems was founded in 2015 by Andrew Feldman, Gary Lauterbach, Michael James, Sean Lie, and Jean-Philippe Fricker. These five founders worked together at SeaMicro, which was started in 2007 by Feldman and Lauterbach and sold to AMD in 2012 for $334 million. The founders knew that GPUs were not the optimal semiconductors for high-level processes. However, they had to design unique cooling methods to prevent a "massive" semiconductor from burning when drawing power, unique software to route around usual microscopic manufacturing defects, and they had to invent a machine that could drill 40 screws into the wafer simultaneously without it cracking. The company had difficulty solving the problem of integrated circuit packaging: adhering the silicon to a motherboard, receiving power, and dealing with heating and cooling and the pipes to deliver and return data. It was burning through $8 million per month and spent $200 million trying to solve the problem. In July 2019, after exhaustive trial and error, the company finally produced a product that worked. In August 2019, Cerebras announced WSE-1, its first-generation Wafer-Scale Engine (WSE) semiconductors and its CS-1 supercomputing system. The CS-1 is a 19-inch rack-mounted appliance and includes a single WSE primary processor with 400,000 processing cores, 1.2 trillion transistors (twelve 100-gigabit ethernet connections), and 18 gigabytes of memory.
helicase Any of a class of ATP-dependent motor proteins that move directionally along the DNA backbone and catalyze the separation of the two complementary strands of double-stranded molecules, permitting a wide variety of vital processes to take place, e.g. transcription, replication, and repair.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.